General Information of Drug (ID: DMQOBH4)

Drug Name
mab 1-7F9 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMQOBH4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IPH-2101 DMDUVCZ Multiple myeloma 2A83 Phase 2 [2]
IPH-2102 DMPBR0D Acute myeloid leukaemia 2A60 Phase 2 [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
IPH-2101 DMDUVCZ Multiple myeloma 2A83 Phase 2 [2]
IPH-2102 DMPBR0D Acute myeloid leukaemia 2A60 Phase 2 [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
IPH-2101 DMDUVCZ Multiple myeloma 2A83 Phase 2 [2]
IPH-2102 DMPBR0D Acute myeloid leukaemia 2A60 Phase 2 [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MHC class I NK cell receptor 2DL1 (CD158A) TT4UXPE KI2L1_HUMAN Not Available [1]
MHC class I NK cell receptor 2DL2 (CD158b1) TTU0P73 KI2L2_HUMAN Not Available [1]
MHC class I NK cell receptor 2DL3 (CD158b2) TTEX3SI KI2L3_HUMAN Not Available [1]

References

1 Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
2 Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.